Autolus Therapeutics (NASDAQ:AUTL) Stock Price Down 5% – Time to Sell?

Autolus Therapeutics plc (NASDAQ:AUTL)’s stock price traded down 5% during trading on Monday . The stock traded as low as $4.55 and last traded at $4.56. 47,927 shares changed hands during trading, a decline of 96% from the average session volume of 1,351,573 shares. The stock had previously closed at $4.80.

Autolus Therapeutics Stock Performance

The company has a fifty day moving average of $3.94 and a 200 day moving average of $4.11. The company has a debt-to-equity ratio of 0.09, a current ratio of 18.55 and a quick ratio of 18.55. The stock has a market cap of $1.21 billion, a P/E ratio of -3.76 and a beta of 2.04.

Autolus Therapeutics (NASDAQ:AUTL) last announced its quarterly earnings data on Thursday, August 8th. The company reported ($0.22) earnings per share for the quarter, missing the consensus estimate of ($0.19) by ($0.03). On average, equities analysts predict that Autolus Therapeutics plc will post -0.84 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Autolus Therapeutics

Several hedge funds have recently made changes to their positions in the business. ProShare Advisors LLC bought a new stake in Autolus Therapeutics during the second quarter worth approximately $43,000. Bayesian Capital Management LP acquired a new stake in shares of Autolus Therapeutics during the 1st quarter valued at $100,000. Daiwa Securities Group Inc. lifted its position in shares of Autolus Therapeutics by 2,659.7% during the 2nd quarter. Daiwa Securities Group Inc. now owns 15,868 shares of the company’s stock valued at $55,000 after acquiring an additional 15,293 shares during the last quarter. B. Riley Wealth Advisors Inc. acquired a new position in shares of Autolus Therapeutics in the 1st quarter worth $108,000. Finally, SG Americas Securities LLC acquired a new position in shares of Autolus Therapeutics in the 1st quarter worth $127,000. Institutional investors and hedge funds own 72.83% of the company’s stock.

About Autolus Therapeutics

Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO4, a programmed T cell investigational therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1 and TRBC2; AUTO6NG, a programmed T cell investigational therapy targeting GD2 in development for the treatment of neuroblastoma; and AUTO8, a product candidate to treat multiple myeloma.